Don't test -- don't treat: the new paradigm for the treatment of prostate cancer?
Albani, J.M.
Missouri Medicine 108(6): 409-412
2011
ISSN/ISBN: 0026-6620 PMID: 22338731 Document Number: 648043
Document emailed within 1 workday
Related Documents
Parkes, C.; Wald, N.J.; Murphy, P.; George, L.; Watt, H.C.; Kirby, R.; Knekt, P.; Helzlsouer, K.J.; Tuomilehto, J. 1995: Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer BMJ 311(7016): 1340-1343O'Dell, K.J.; Volk, R.J.; Cass, A.R.; Spann, S.J. 1999: Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? Journal of Family Practice 48(9): 682-688
Srinualnad, S.; Charoenkraikamol, C.; Toraksa, S.; Uiprasertkul, M.; Amornvesukit, T.; Taweemonkongsap, T.; Udompunturak, S.; Nualyong, C.; Tantiwong, A. 2006: Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day) Journal of the Medical Association of Thailand 89(1): 37-42
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
2008: Group B strep in pregnancy: test-and-treat, or just treat? Journal of Family Practice 57(1): 11
Horiguchi, A.; Hatakeyama, N.; Ikeuchi, K. 1999: Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35
Habib, F.K.; Ross, M.; Bayne, C.W. 1999: Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer European Urology 35(5-6): 439-442
Seikkula, H.; Pettersson, K.; Boström, P.J. 2015: PSA and blood test diagnostics of prostate cancer Duodecim; Laaketieteellinen Aikakauskirja 131(17): 1547-1552
Wagner, B.G.; Blower, S. 2012: Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance and treatment costs Plos one 7(9): E41212
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352
Lifson, A.R.; Demisse, W.; Ketema, K.; Tadesse, A.; May, R.; Yakob, B.; Slater, L.; Shenie, T. 2013: Failure to test for HIV in rural Ethiopia: knowledge and belief correlates and implications for universal test and treat strategies Journal of the International Association of Providers of Aids Care 12(5): 306-311
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Kabogo, J.; Muniu, E.; Wamunyokoli, F.; Musoke, R.; Songok, E. 2018: Evidence of reduced treatment adherence among HIV infected paediatric and adolescent populations in Nairobi at the onset of the UNAIDS Universal Test and Treat Program Bmc Research Notes 11(1): 134
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Karamanolakis, D.; Lambou, T.; Bogdanos, J.; Milathianakis, C.; Sourla, A.; Lembessis, P.; Halapas, A.; Pissimissis, N.; Dessypris, N.; Petridou, E.T.; Koutsilieris, M. 2006: Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml) Anticancer Research 26(4b): 3159-3166
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747